Mesirow Financial Investment Management Inc. Invests $223,000 in Surmodics, Inc. (NASDAQ:SRDX)

Mesirow Financial Investment Management Inc. purchased a new stake in shares of Surmodics, Inc. (NASDAQ:SRDX) during the first quarter, Holdings Channel.com reports. The fund purchased 7,614 shares of the company’s stock, valued at approximately $223,000.

Other large investors also recently made changes to their positions in the company. Strs Ohio lifted its holdings in Surmodics by 97.2% during the fourth quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after acquiring an additional 3,500 shares during the period. Panagora Asset Management Inc. increased its position in shares of Surmodics by 109.8% during the 4th quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock valued at $1,624,000 after purchasing an additional 23,379 shares during the last quarter. Hillsdale Investment Management Inc. raised its stake in shares of Surmodics by 15.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock worth $166,000 after purchasing an additional 620 shares during the period. US Bancorp DE boosted its holdings in shares of Surmodics by 61.9% in the 4th quarter. US Bancorp DE now owns 16,190 shares of the company’s stock worth $589,000 after buying an additional 6,193 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in Surmodics during the fourth quarter valued at about $504,000. 96.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Wednesday, May 29th. StockNews.com assumed coverage on shares of Surmodics in a report on Tuesday. They issued a “hold” rating on the stock. Barrington Research reissued a “market perform” rating on shares of Surmodics in a report on Thursday, May 30th. Lake Street Capital restated a “hold” rating and issued a $43.00 price objective on shares of Surmodics in a research note on Wednesday, May 29th. Finally, Sidoti reissued a “neutral” rating and set a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Price Performance

Shares of NASDAQ:SRDX traded up $0.01 on Wednesday, hitting $41.98. The company’s stock had a trading volume of 142,547 shares, compared to its average volume of 162,966. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.36. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.39 and a quick ratio of 3.59. The company has a market capitalization of $598.63 million, a PE ratio of 44.18 and a beta of 1.18. The company has a 50-day simple moving average of $37.02 and a 200 day simple moving average of $33.47.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.43. The company had revenue of $31.96 million during the quarter, compared to the consensus estimate of $28.79 million. Surmodics had a net margin of 9.44% and a return on equity of 13.30%. During the same period in the previous year, the firm posted ($0.40) EPS. Sell-side analysts forecast that Surmodics, Inc. will post -0.51 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).